Posts Tagged ‘Amgen’

Rethinking the Dosing of Obesity Medicines with AMG 133

February 6, 2024 — We learned recently that questions about the need for ongoing dosing with obesity medicines raise discomforting thoughts. After all, obesity is a chronic disease, so we can’t dispute the need for continued daily or weekly doses with obesity medicines. Or can we? Amgen seems to think we can. Monthly Dosing? Induction and Maintenance? With a […]

Amgen Bringing More Competition into Obesity

December 5, 2022 — Move over, Novo Nordisk and Eli Lilly. Amgen wants a piece of the action in obesity treatment. With some obvious pride of accomplishment, Amgen unveiled results from a phase 1 study of its dual action conjugate on Saturday. This new experimental drug, AMG 133, is a molecule that combines peptides to activate GLP-1 receptors (as […]

A New Protein with Promising Effect for Obesity

October 23, 2017 — It’s early days for this new protein, but worth noting, nonetheless. Amgen scientists have successfully demonstrated that they can modify a GDF15 protein to treat obesity in mice, rats, and primates. With animal data published in Science Translational Medicine, they show an impressive effect on body weight in mice and monkeys. Acting on the Gut […]